VIROBIX

Precision Gene Delivery for Cancer

Systemic Viral Delivery of Potent RNA Therapeutics to Hard-to-Treat Cancers

The Need

- ❑ Unmet clinical need: late-stage cancers
- ❑ IO unresponsive ~80B$ solid tumors market
- ❑ Efficacy limited by systemic toxicity
- ❑ Cytokines work → but can't be safely delivered
- ❑ Viral vectors lack tumor specificity
- ❑ Most viral dose is sequestered by normal tissue

Our Solution: Tumor-Targeted Viral Platform

- ❑ Native viral vector + external engager
- ❑ No coat engineering → full potency retained
- ❑ IV-ready vector
- ❑ Tumor-marker gated entry
- ❑ Programmable payloads: cytokines, immune modulators, checkpoint inhibitors
- ❑ Modular-rapid retargeting across indications

Technology







Pipeline: Expansion-ready



Lead Target: CEACAM6

- ❑ 80-90% of solid tumors (Pancreatic, Lung, Ovarian, Colorectal)
- ❑ Poor prognosis marker

IP & Development Status

- ❑ 2 Patents from Weizmann institute of science, TS discussions
- ❑ Next IP: viral cassette payloads
- ❑ Initial POC in-vitro, supportive in-vivo
- ❑ External in-vitro and in-vivo validation

CEO CO-FOUNDER

Dr. Diana Gataulin

Co-inventor Theraputic dev. BD& Strategy

CSO CO-FOUNDER

Dr. Eyal Zoler

Virology & cytokine engineering expert

SCIENTIFIC ADVISOR

Prof. Menachem Rubinstein

Core technology inventor; creator of Roferon-A™, Rebif™ Enbrel™

Near term developmental plan:

- ❑ **6-9m**: Candidate optimization and selection, efficacy in human relevant models/organoids, ITF/interact)
- ❑ **18-24m**: Non-GLP tox, CMC feasibility, pre-IND, platform expansion

Summary

Selective tumor killing

Safe | Flexible | Shielded

Contact

virobixcompany@gmail.com

www.virobix.com

Supporters and traction:

WEIZMANN INSTITUTE OF SCIENCE · PEARL COHEN · Nucleate · NEST CATALYST · Colab square